Active, not recruitingPhase 2NCT05092776

Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine

Studying Familial Mediterranean fever

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
R-Pharm International, LLC
Principal Investigator
Mikhail Samsonov
R-Pharm
Intervention
RPH-104(biological)
Enrollment
84 enrolled
Eligibility
18 years · All sexes
Timeline
20212025

Study locations (14)

Collaborators

Data Management 365 · Atlant Clinical LLC · R-Pharm JSC · Unimed Laboratories · Exacte Labs LLC · Key Stat LLC · TRPharm İlaç Sanayi Ticaret Anonim Şirketi and ASCOT SCIENCE Education and Consulting Ltd. · Ascot Eğitim ve Danışmanlık LTD. ŞTİ.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05092776 on ClinicalTrials.gov

Other trials for Familial Mediterranean fever

Additional recruiting or active studies for the same condition.

See all trials for Familial Mediterranean fever

← Back to all trials